In the News

Learn more about HPV and cancer risk in the Hispanic community, which has more cancers linked to the disease than any other group in the United States.

Researchers have found that the genetic changes that cause pediatric leukemia are different from those that lead to leukemia in adults.

Learn about the latest guidelines for Pap tests, HPV tests, and pelvic exams — including recently updated recommendations.

A new project called the BRCA Exchange is sharing data about BRCA mutations and what they actually mean for cancer risk.

A recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.

MSK colleagues pay tribute to molecular biologist Jerard Hurwitz’s scientific accomplishments and passion for discovery.

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

Research is focusing on ways to help cancer-fighting immune cells stick around longer, boosting their effectiveness.

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

Experience the words and artwork of three patients who found hope and healing through MSK art programs.